Navigation Links
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
Date:7/27/2009

y this result and will be working closely with our clinical team to evaluate these data and the available data from MAESTRO-02 and MAESTRO-03 to determine our next steps," said Kevin Giese, President and CEO of BioMS Medical. "We are fortunate to have suitable resources in place to remain flexible to pursue whatever options emerge once we understand these results more fully."

BioMS Medical Webcast

Participants may listen to a discussion of the outcome of the MAESTRO-01 study by Kevin Giese, President and CEO of BioMS Medical. The audio webcast is accessible through the Company's web site at www.biomsmedical.com.

About MAESTRO-01

MAESTRO-01 was a multi-center, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of dirucotide in patients with SPMS. The study was conducted in Canada and nine countries in Europe and included 612 patients being administered either dirucotide or placebo intravenously every six months for a period of two years.

The primary clinical endpoint for the trial was defined as a statistically significant increase in the time to progression of the disease, as measured by the EDSS, in patients with HLA-DR2 and/or HLA-DR4 immune response genes. It is estimated that up to 70% of all multiple sclerosis patients are HLA-DR2 and/or HLA-DR4 positive(i). The EDSS is the standard for measuring impairment in MS.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, progressive, often disabling disease that attacks the central nervous system(ii). MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, resulting in disrupted nerve impulses traveling to and from the brain and spinal cord(iii). Symptoms of MS may include vision problems, loss of balance, numbnes
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
2. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
3. MADIT-CRT Trial Meets Primary Endpoint
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
6. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
7. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
8. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
11. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015   Temptime Corporation , ... health care industry, announced today that its board of ... to chief executive officer.  Mr. Van den ... since 2011. "Renaat deeply values Temptime,s mission ... job of expanding Temptime,s products and services to organizations ...
(Date:5/5/2015)... , May 5, 2015 Sysmex America, ... equipment and information systems technology, today announces a ... company. This partnership allows Sysmex and its distributor ... solution for physician offices and clinics that connect ... Electronic Medical Record (EMR) systems. Physician ...
(Date:5/5/2015)... May 5, 2015  IBM Watson Health (NYSE: ... more than a dozen leading cancer institutes to accelerate ... options for their patients. The institutes will apply ... from weeks to minutes the ability to translate DNA ... information from medical literature to personalize treatment options. The ...
Breaking Medicine Technology:Temptime President Renaat Van den Hooff Promoted to CEO 2Sysmex America, Inc. Partners with Medicus Middleware to Provide Physician Office Labs with Instrument Connectivity Directly to EMR 2Sysmex America, Inc. Partners with Medicus Middleware to Provide Physician Office Labs with Instrument Connectivity Directly to EMR 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6
... Inc. (Nasdaq: HALO ), a biopharmaceutical company ... , today announced it plans to report first quarter ... the open of the financial markets. The announcement will ... community at 8:00 a.m. PDT (11:00 a.m. EDT), which ...
... Zimmer Holdings, Inc. (NYSE and SIX: ZMH), ... it will be participating in the Deutsche Bank ... The InterContinental Hotel in Boston, Massachusetts, on May ... A live webcast of the presentation ...
Cached Medicine Technology:Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2Zimmer Holdings to Present at Deutsche Bank Securities, Inc. 36th Annual Health Care Conference 2
(Date:5/5/2015)... 06, 2015 The Journal ... research “ Priority interventions to improve the management ... participatory research of the ACCORD program ” , ... care actors, including clinicians, patients and family members, ... management which included knowledge gap, “work in silos”, ...
(Date:5/5/2015)... Hills Cosmetic Dentist, Arthur Glosman released a luxury line of ... the offices of Arthur Glosman DDS, 450 N Roxbury Drive ... online store . “I wanted to be one of the ... beauty with a luxurious collection of products designed to make ... Dr. Glosman’s Advanced Dental Health + Beauty™ products use a ...
(Date:5/5/2015)... Carlini CPA, PLLC is a full service ... surrounding areas. The company has over 25 years of ... assistance in making informed decisions about finances. Client service ... tax returns for their clients. , Portal Safe ... (and Carlini CPA) to pass documents back and forth ...
(Date:5/5/2015)... AZ (PRWEB) May 05, 2015 NCPDP ... Elite Partner Program. The program establishes a three-year commitment ... a maximum of 10 Elite Partners. “AmerisourceBergen has supported ... Stember, President of NCPDP, “and this is a wonderful ... , We can trace AmerisourceBergen back to our ...
(Date:5/5/2015)... “Given that Hispanics are one in six people in the ... major step in the arsenal of facts documenting that we ... years, data have accumulated that the health of Hispanics did ... and the need to create new models of health and ... Jane L. Delgado, PhD, MS, President and CEO of the ...
Breaking Medicine News(10 mins):Health News:Priority interventions in chronic non-cancer pain published by Dove Medical Press 2Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:“Its about time,” Declares the National Alliance for Hispanic Health on First CDC Study of Hispanic Health 2
... of getting on fire due to the recent desert fire in ... by continuous heavy hot desert winds//. Most of the homes and ... factory which is considered to be highly toxic is in the ... a tough time controlling the fire from spreading with most of ...
... A new study has now confirmed an ancient myth that coco ... it contains certain chemicals that can limit the development of fluids ... dates back to as early as 16th century by ancient South ... regarding the qualities of the cocoa bean or more specifically why ...
... Merck Pharmaceuticals from Germany and Takeda Pharmaceuticals from Japan ... , ,Matuzumab is developed by Merck which is ... Pharmaceuticals will sign agreement with Merck to give royalty ... will pay 60 million euros to Merck with an ...
... gene mutation is associated with the neurological disorder called ... associated with chronic pains. // , ,HNA episodes ... or overworking the arms and shoulders. Nerve inflammation and ... person's immune response are contributing to the episode. The ...
... made by researchers at Wake Forest University School of Medicine said ... are quite high and it is also linked to the emphasis ... rates of musculoskeletal injuries. Almost half of workers reported pain in ... five of those workers was unable to work for at least ...
... 65 years and above may have a sedentary lifestyle if they ... is known through earlier studies that fewer than 40 percent of ... can extend their years of independent life., ,A new UCLA ... is, for what one can do at an advanced age — ...
Cached Medicine News:Health News:Injury Rates High For Workers In Poultry Farms 2
Rapid Exchange Stent Delivery System with Hepacoat...
6.5mm diameter handpiece; 75mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper....
3 Piece with .35mm Angled Point, Curved to Left, #8, Side Opening Irrigation, 40mm overall length; in stainless steel; 30cm Long Silicone Tubing with Connector....
5x6mm Loop, 2 Irrigation Ports at 10, 2 O'Clock, 18 Gauge Thin Walled 1.2mm Shaft; overall length 40mm; stainless steel...
Medicine Products: